Long-term survival of segmental pancreas isografts in NOD/Lt mice treated with anti-CD4 and anti-CD8 monoclonal antibodies
- Author(s)
- Mottram, PL; Murray-Segal, LJ; Han, WR; Maguire, J; Stein-Oakley, A; Mandel, TE;
- Details
- Publication Year 1998-09,Volume 47,Issue #9,Page 1399-1405
- Journal Title
- DIABETES
- Publication Type
- Journal Article
- Abstract
- Spontaneously diabetic nonobese diabetic (NOD/Lt) mice were treated with anti-T-cell monoclonal antibodies (mAbs) at the time of grafting with vascularized segmental pancreas isografts. Recipients were either untreated or given anti-CD4 and/or anti-CD8 mAbs (0.5 mg/20-g mouse on each of 4 consecutive days), which reduced target cell levels to <5% of normal. Graft function was monitored by measuring blood glucose (BG) levels. Transplants were removed for histological examination when BG returned to >20 mmol/l for two consecutive readings. Isografts from 3- to 4-week-old prediabetic mice placed in untreated diabetic NOD mice ceased functioning in 9-13 days with a mean survival time (MST) +/- SD of 10 +/- 2. Treatment with anti-CD4 prolonged survival significantly (MST = 61 +/- 35 days, P < 0.05 compared with untreated control mice). Anti-CD8 treatment was less effective, but it still significantly improved graft survival (MST = 24 +/- 9 days, P < 0.05 compared with untreated control mice). Anti-CD8 plus anti-CD4 treatment was highly effective in inhibiting autoimmune destruction of the grafts (MST = 97 +/- 8 days). This clearly demonstrates that transient inactivation of most T-cells with anti-CD4 plus anti-CD8 mAbs effectively controls autoimmune disease in the isograft, despite recovery of CD4 and CD8 T-cells to normal levels. Although insulitis developed in the longterm grafts, insulitis scores did not increase between 33 and 100 days, and none of the mice progressed to IDDM in 100 days. Histology showed a predominantly peri-islet T-cell and macrophage infiltrate with ductal expression of the cytokines interleukin (IL)-4, IL-2, and interferon-gamma. There was little infiltrate or expression of cytokines within the islets. Thus, mAb treatment at the time of grafting allowed isograft survival and prevented progression from insulitis to beta-cell destruction.
- Publisher
- AMER DIABETES ASSOC
- Keywords
- NONOBESE DIABETIC MICE; BETA-CELL DESTRUCTION; INTERFERON-GAMMA; ISLET ISOGRAFT; MOUSE; TRANSPLANTATION; EXPRESSION; INSULITIS; ALLOGRAFTS; REJECTION
- Publisher's Version
- https://doi.org/10.2337/diabetes.47.9.1399
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 1998-09-01 12:00:00